EyePoint Pharmaceuticals Inc

NASDAQ:EYPT  
14.50
-1.10 (-7.05%)
Products, Regulatory, Earnings Announcements

EyePoint Pharmaceuticals Reports Positive Interim Safety & Efficacy Data From Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 For Treatment Of Wet AMD

Published: 11/13/2021 15:17 GMT
EyePoint Pharmaceuticals Inc (EYPT) - Eyepoint Pharmaceuticals-reports Positive Interim Safety & Efficacy Data From Phase 1 Davio Clinical Trial Evaluating Eyp-1901 for Treatment of Wet Amd.
Eyepoint Pharmaceuticals- Interim Six-month Results Show Positive Safety Data, No Dose Limiting Toxicities.
Eyepoint Pharmaceuticals- Interim Six-month Results Show No Ocular Serious Adverse Events (saes), and No Drug-related Systemic Saes.
Eyepoint Pharmaceuticals - 76% and 53% of Patients Were Rescue-free Up to Four & Six Months, Respectively, After Single Injection of Eyp-1901.
Overall Treatment Burden Reduced by 79% at Six Months.
Phase 2 Clinical Trials Expected to Initiate in 2022.
Revenue is expected to be $9.79 Million
Adjusted EPS is expected to be -$0.52

Next Quarter Revenue Guidance is expected to be $12.25 Million
Next Quarter EPS Guidance is expected to be -$0.65

More details on our Analysts Page.